anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Self-organized niobium oxide nanocones with nano-sized tips are prepared by anodization of niobium in the presence of an electrolyte such as hydrofluoric acid (HF) (aq.). Dimensions and integrity of the bulk nanostructures formed are strongly dependent on potential, temperature, electrolyte composition, and anodization times. Accordingly, the morphology, topology, uniformity and bioactivity of the niobium oxide nanostructures formed can be readily adjusted by adjusting these anodization parameters. A bioactive form of crystalline niobium oxide is formed by anodizing niobium metal in the presence of an electrolyte that includes HF and at least one salt such as Na 2 SO 4  or NaF. One property of bioactive niobium oxide formed by anodizing niobium metal in the presence of HF (aq.) is its ability to interact with hydroxylapatite.
Patients receive standard high-dose IL-2 therapy, with an opportunity to crossover to the experimental arm if there is disease progression noted after two cycles of high-dose IL-2. Crossover patients will be included in Arm A.
A central facility communicates with a portable container via a mobile device. A computer at the central facility receives (a) usage data, in association with identification tag information for the portable container, from the mobile device associated with the portable container, the usage data generated by a usage sensor in the portable container, (b) environmental data from the mobile device associated with the portable container, the environmental data generated by an environmental sensor, and (c) patient data from the mobile device associated with the portable container, the patient data generated by a patient sensor. The central facility computer stores the usage data, the environmental data and the patient data in a record associated with the identification tag information. The central facility computer analyzes the usage data, the environmental data and the patient data relative to a situational rule, to determine an action. The central facility computer sends (i) action data to the mobile device associated with the portable container, and (ii) notice data to a third party in accordance with a notification rule. The central facility computer stores the action data and the notice data in the record associated with the identification tag information.
Fertility preservation is an important aspect of care for all patients who may have their fertility compromised secondary to disease, medical treatments, age or other circumstances, including treatments for gender dysphoria. An increasing number of transgender male patients (transitioning female to male) are presenting to fertility clinics for fertility preservation. Studies indicate that parenthood is important for this patient population . Therefore, both the Endocrine Society and the World Professional Association for Transgender Health (WPATH) recommend that fertility preservation be discussed with all patients prior to initiation of medical treatments for gender dysphoria.

For transgender male patients, medical treatment is primarily comprised of testosterone, which is often preceded by GnRH agonists (such as leuprolide acetate) to reduce endogenous estrogen production. There are theoretical concerns about the effects of long-standing hormonal treatment on the gonads and future fertility potential. Regardless of the timing of initiation of GnRH agonist and/or testosterone therapy, fertility preservation counseling is an essential aspect of their care. Egg preservation does require the individual to undergo their natal puberty, and for many trans-males, this is undesirable and even contra-indicated from mental health standpoint, as the suicide rate for transgender youth is 10-times the national average. Ovarian tissue cryopreservation is an alternative option for transgender male patients who desire pubertal blockade and testosterone but have not yet gone through female puberty and are therefore not producing mature eggs.
This invention describes a novel polysaccharide prodrug of 5-fluorouracil (5-FU) with enhanced target specificity for colorectal cancer treatment, and its preparation methods. The prodrug is synthesized by chemically linking anti-cancer drug 5-fluorouracil (5-FU) with a specially selected polysaccharide with molecular weight of 10 5 ˜10 7  Da containing galactose residues. Its distinctive characteristics are that it is a prodrug synthesized by chemically linking polysaccharides with 5-FU through different bridge links for the targeted treatment of colorectal cancer; that the polysaccharides in the chemical compound contain galactose residues; and that these polysaccharides are prepared from natural gums or plant materials. Due to these unique characteristics, as an oral preparation, the polysaccharide component of this novel prodrug can protect the active agent 5-FU from absorption (or metabolism) in the upper gastrointestinal tract and deliver a high concentration of the 5-FU to the colorectal area. Upon reaching the colorectal area, the 5-FU-galactose portion of the prodrug will bind to galectin-3, a-galactoside-binding protein implicated in tumor progression by interactions with its ligands, such as TF (Thomsen-Friedenreich, Galb3GalNAc), Tn (GalNAcaThr/Ser), and Sialy-Tn with galactose residues, which are highly expressed among colorectal cancer cells. Finally, the active 5-FU component will be released locally from the polysaccharide via enzymatic hydrolysis from the local bacterial flora, allowing it to actively kill the colorectal cancer cells. In summary, this novel target-specific prodrug can enhance the selectivity of 5-FU and increase its therapeutic effects in the treatment of colorectal cancer. In addition, with this enhanced target specificity, it is possible to maximize the 5-FU efficacy in cancer patients by having either less toxicity with the same or higher therapeutic dose, and/or administer a lower dosage (if so desired) to achieve the same therapeutic effects, but with much less toxicity. Multiple examples of various approaches to synthesize this novel prodrug are enclosed herein along with several animal model experiments to substantiate the claims as stated above.
Huntington's disease (HD) is a progressive and fatal neurologic disorder caused by an expanded CAG repeat in the gene coding for a protein of unknown function that has been named huntingtin. The exact cause of neuronal death in HD is unknown, however, the leading hypothesis is that of excitotoxicity and apoptosis induced by a defect in energy metabolism that may be caused by oxidative stress. We previously demonstrated that mitochondrial inhibitors produce striatal lesions closely mimicking the phenotype of HD. We have also shown that oxidative injury is involved in these models and may be in human HD. Because of this research, there has been increasing interest in the HD field in exploring complementary agents that might prevent oxidative injury, Creatine is a widely used dietary supplement principally taken to enhance athletic performance. It is a very strong candidate neuroprotective agent for HD and other neurodegenerative disorders because of its ability to ameliorate toxin-based animal models and because of our preliminary evidence in transgenic HD mice. However, there is only limited animal experience with creatine and there has not yet been any trials in humans with neurodegenerative disorders. There are several potential mechanisms by which creatine could be an effective treatment for HD. First, there is evidence that it can be neuroprotective by relieving oxidative stress. Second, it could directly inhibit apoptotic neuronal death through its inhibitory action on the mitochondrial transition pore. Third, we have preliminary evidence that creatine treatment may be associated with reduced huntingtin aggregation, a potentially toxic process. Finally it could act peripherally to help reverse the weakness and muscle mass loss that is a major clinical problem in HD. We have preliminary evidence that creatine can extend survival in transgenic models of HD and that it can reduce brain markers of metabolic stress in humans with HD. We propose to test whether creatine can ameliorate the behavioral and neuropathologic phenotypes occurring in transgenic models of HD, examine the potential mechanisms of creatine neuroprotection, test its safety and tolerability in HD patients, and collect pilot clinical data examining how creatine impacts HD symptoms and progression. These studies are intended to provide the basis of a subsequent phase III trial of creatine in HD.
PCT No. PCT/SE85/00431 Sec. 371 Date Jul. 8, 1986 Sec. 102(e) Date Jul. 8, 1986 PCT Filed Nov. 5, 1985 PCT Pub. No. WO86/02837 PCT Pub. Date May 22, 1986.The adhesion of non-pathogenic bacteria to the stomach and intestines of humans and animals is increased by the administration of the bacteria in the presence of a protein, designated adhesive promoting protein, which can be produced by cultivating lactic acid bacteria in a medium with the addition of forms of sugar of enhanced concentration. A preparation to increase said adhesion contains non-pathogenic bacteria cultivated in the manner described above, together with adhesive promoting protein.
PURPOSE:To obtain a composition for cleansing the skin, excellent in foaming power, capable of simultaneously washing foulings sticking to the skin surface and sulci cutis and providing an excellent touch due to the lubricity on the skin in use, hardly causing irritation to the skin after the use and providing a good touch. CONSTITUTION:This composition for cleansing the skin contains (A) 1-90wt.% higher fatty acid salt, e.g. potassium laurate or potassium myristate, (B) 0.01-20wt.% water-insoluble solid powder, e.g. an inorganic substance powder having 0.01-10mum average particle diameter or an organic substance powder having 10mum to 1mm average particle diameter, (C) 0.1-30wt.% amino acid-based surfactant having acylated N, e.g. an acylaminocarboxylic acid, an acylaminosulfonic acid or an amidoamine type amphoteric surfactant and further, as necessary, (D) 0.1-10wt.% amine oxide, e.g. a compound of the formula (R1 is a 10-20C alkyl or alkenyl; R2 and R3 are each a 1-3C alkyl). The foaming power and touch after use thereof are more improved by blending the ingredient (D) therein.
Supplemental feedings in the neonatal intensive care unit (NICU) are common due to the separation of mother and neonate and/or complex medical issues that make direct breastfeeding difficult. The Supplemental Nursing System (SNS) is utilized infrequently in the NICU and there is little data available to compare breastfeeding outcomes of mothers who supplement by bottle compared to SNS. The aims of this study are to understand whether supplementation by SNS improves breastfeeding outcomes compared to neonates supplemented by bottle. From December 1, 2018 - November 30, 2019 there were 195 neonates admitted to Children's Hospital Colorado (CHCO) with a primary diagnosis of hyperbilirubinemia who were born at 37 weeks or greater. This makes up approximately 13.7% of all admissions during that time frame. This is a population of mothers at risk for cessation of exclusive breastfeeding due to the necessity of supplementation. These neonates are frequently supplemented because the mother's milk typically is not yet in to support adequate nutritional intake. These neonates are not often medically complex or have any factors that would bias the results of this study.
Placebo - subjects will take 200 mg twice daily, orally (approximately 8am and 8pm) for twelve weeks starting seven days prior to the assigned quit date. They will also receive smoking cessation behavioral counseling.
A topical hair treatment or a topical dermatological or cosmetic composition includes a liquid having approximately 0.2 to 0.5 mg/mL of a xanthene derivative. The xanthene derivative can be a methylxanthene. The methylxanthene can be theophylline, caffeine, and/or theobromine. Preferably, the methylxanthene is caffeine selected from hydrous caffeine, caffeine salts, and complexes dissociated to yield caffeine. Caffeine is present in an amount of approximately 0.3 mg/mL. There is also provided a saw palmetto berry derivative present in the liquid in an amount of approximately 0.02 to 0.05 mg/mL. Preferably, the saw palmetto berry derivative is saw palmetto berry extract, in particular, hydrous saw palmetto berry extract. The saw palmetto berry extract is present in said liquid in an amount of approximately 0.03 mg/mL. The liquid can be a shampoo, a conditioner, and/or a combination shampoo and conditioner.
Headache is a common health problem that affects quality of life in an older population and imposes substantial economic costs. Headache changes with age. Features of headache become less typical and neck pain is more frequently associated with headache in older persons. We recently demonstrated that the presence of cervical musculoskeletal impairment is not specific to cervicogenic headache (headache caused by the neck). Rather it was present in various frequent intermittent headache types in elders when compared to elders without headache. Changes in headache characteristics with age play an important role not only in diagnosis but also in treatment choice. Impairment in cervical musculoskeletal function found in older persons with headache has implications for headache management choices as the evidence indicates that physiotherapy management methods such as manual therapy and therapeutic exercise are an effective management approach for headache associated with the neck. Physiotherapy treatment would be a safe therapeutic option and may have a beneficial effect for elders with headache who have neck pain and concomitant cervical musculoskeletal dysfunction. This is particularly relevant as there are widespread concerns about medication overuse, adverse drug events and drug interactions in older persons. The effective management of older persons with headache in particular of those with atypical features of headache remains a challenge. Physiotherapy is indicated in those older persons diagnosed with cervicogenic headache but could also be adjunct treatment for those with cervical musculoskeletal signs who are suspected of having transitional headache. At present, there has been no trial to date which has investigated the effectiveness of physiotherapy treatment specifically for older persons with various types of headache with associated neck pain and cervical musculoskeletal impairment. A clinical trial of treatment of cervical musculoskeletal impairment in older persons with various headache types may help guide management of headache in attempts to lesson medication use and cost in this population. Physiotherapy management may be a worthy treatment option particularly in older persons with headache who do not respond well to medication.
Moulding compsns. contain a water soluble alginate, filler, gelling agent, inhibitor, and 0.01-2.5 wt. % potassium diphosphate as control agent. The compsn. is used for dental moulds and has a higher flow and lower gel and set times than other compsns. thus enabling truer moulds to be taken. The moulding material is also cheaper and longer lasting as less alginate is used.
Alogliptin 25 mg, tablets, orally, once daily for up to 12 months. Participants will receive interventions as part of routine medical care.
PURPOSE:To accelerate the ripening of plum liquor, etc., by generating high-frequency voltage from a high-frequency voltage generator, applying the high-frequency voltage to the electrodes of an ultrasonic vibration element via a feeding contact and a receiving contact, and applying ultrasonic vibration to the liquid in a cup. CONSTITUTION:Receiving contacts 1h and 1i connected to the electrodes 1f and 1g of an ultrasonic vibration element 1e are exposed to the bottom surface of a cup 1, and a power source to drive the ultrasonic vibration element 1e is placed in the bed 20 on which the bottom of the cup is placed. The power source contains a high-frequency voltage generator 2d to supply high-frequency voltage to the ultrasonic vibration element 1e. The output circuit of the generator 2d is connected to the feeding contacts 2b and 2c, which are exposed to the positions corresponding to those of the receiving contacts placed on the bed. Switches 3, 4 interrupting the circuit from the generator plug 2e to be connected to an external power source, via the high-frequency voltage generator 2d to the feeding contact, are attached to the top face of the bed 20. The switches are turned on by placing the cup 1 on the bed.
Streptococcal Infections Group A—Infections of the upper-respiratory tract, skin and soft-tissue infections, scarlet fever, and erysipelas.

The following doses are recommended:

Adults and pediatric patients over 60 lbs. in weight: 2,400,000 units.

Pediatric patients from 30 to 60 lbs.: 900,000 units to 1,200,000 units.

Pediatric patients under 30 lbs.: 600,000 units.

NOTE: Treatment with the recommended dosage is usually given at a single session using multiple IM sites when indicated. An alternative dosage schedule may be used, giving one-half (1/2) the total dose on day 1 and one-half (1/2) on day 3. This will also insure the penicillinemia required over a 10-day period; however, this alternate schedule should be used only when the physician can be assured of the patient's cooperation.
Method of treatment of Duchenne muscular dystrophy includes preparation and injection of medications obtained from embryofetal material and cells separated from it in the form of suspension with the stem cells. At least two medications are produced and injected in the form of suspension of cryopreserved stem cells separated from human fetus of 5-12 gestation weeks. One of the suspensions contains stem cells obtained from fetus liver, and another contains stem cells from fetus brain. The suspension with the stem cells from fetus liver is injected in the amount of at least 0,1 ml, where the number of nucleated cells is not less than 3,72 x 1 ml per one injection. The suspension with the stem cells from fetus brain is injected in the amount of at least 1,14 × 1 ml per one injection. Before the suspension with the stem cells from fetus liver s injected, it is necessary to conduct premedication.
Fatal anaphylactic shock was reported following injection of a larger than normal volume of ETHAMOLlN Injection into a male who had a known allergic disposition. Although there are only three known reports of anaphylaxis, the possibility of an anaphylactic reaction should be kept in mind, and the physician should be prepared to treat it appropriately. In extreme emergencies, 0.25 mL of a 1:1,000 intravenous solution of epinephrine (0.25 mg) should be used, and allergic reactions should be controlled with antihistamines.

Acute renal failure with spontaneous recovery followed injection of 15 to 20 mL of ETHAMOLIN Injection into two women.

The physician should bear in mind that severe injection necrosis may result from direct injection of sclerosing agents, especially if excessive volumes are used. At least one fatal case of extensive esophageal necrosis and death has been reported. The drug should be administered by physicians who are familiar with an acceptable injection technique.

Patients in Child Class C are more likely to develop esophageal ulceration than those in Classes Aand B. Complications of ulceration, necrosis, and delayed esophageal perforation appear to occur more frequently when ETHAMOLIN Injection is injected submucosally. This route is not recommended.

In patients with concomitant cardiorespiratory disease, careful monitoring and minimization of the total dose per session is recommended.

Fatal aspiration pneumonia has occurred in elderly patients undergoing esophageal variceal sclerotherapy with ETHAMOLIN Injection. This adverse event appears to be procedure-related, rather than drug-related; but, as aspiration of blood and/or stomach contents is not uncommon in patients with bleeding esophageal varices, special precautions should be taken to prevent its occurrence, especially in elderly and critically-ill subjects.
PURPOSE: Bariatric surgery poses an ever-increasing importance in the effective and long-lasting treatment of obesity, a condition strongly associated with inflammation and increased risk of other diseases and health problems. In obesity-related inflammation, maintaining a balance between pro-inflammatory and anti-inflammatory cytokines is crucial. In this study, we examined early effects of laparoscopic sleeve gastrectomy (LSG) on inflammatory and anti-inflammatory cytokines in obese patients, and assessed their effect on postoperative weight loss.
MATERIALS AND METHODS: This prospective cohort study was conducted from September 2022 till June 2023. Fifty obese adults were enrolled for LSG. All patients underwent assessments of body measurements, as well as levels of interleukin-6 (IL-6), interleukin-10 (IL-10), and TNF-alpha at baseline and 3 months postsurgery. We developed a decision tree model to predict the success of weight loss.
RESULTS: At 3 months postsurgery, patients lost 18.9 ± 6.9 kg of excess body weight. A significant decrease was observed for IL-10 (p < 0.0001), simultaneously with a significant increase in IL-6 (p < 0.0001). We found that high IL-6 (> 1.169 pg/mL) levels could contribute to an effective weight loss among patients with a baseline BMI less than 47.46 kg/m2.
CONCLUSION: Study revealed that 3 months after bariatric surgery, inflammation persists, and its markers significantly influence postoperative weight loss, as indicated by BMI range. Distinct behaviors of IL-10 and IL-6 in relation to obesity underline the necessity of considering individual cytokine profiles when evaluating bariatric surgery outcomes.
The present invention relates to a composition for the treatment, improvement, or prevention of skin pigmentation diseases or symptoms, or a skin whitening composition, containing a Dendropanax morbiferus Lev. leaf extract and a new active ingredient isolated therefrom as active ingredients. The extract and the new active ingredient isolated therefrom of the present invention have exhibited an excellent effect for inhibiting the melanin production in melanoma and the expression of melanin production-related proteins (MITF, Tyrosinase, TRP-1, TRP-2). Therefore, the extract and the new active ingredient isolated therefrom can be usefully used as a cosmetic composition for preventing or treating various pigmentation diseases including hyperpigmentation. The composition with whitening activity containing the Dendropanax morbiferus Lev. leaf extract and two new single ingredients as active ingredients can be used as a pharmaceutical composition, a cosmetic composition, or a food composition capable of preventing or treating various pigmentation diseases including hyperpigmentation.
Tinnitus-retraining therapy will be offered in the control arm which represents the standard evidence-based intervention on the NHS. (2) Participants enrolled to this arm will undertake tinnitus retraining therapy with a trained audiologist. The sessions will last 30 minutes with the option for further sessions should the patient which to have more support with their tinnitus to mimic the NHS programme as much as possible. These sessions will encompass a brief audiological history followed by therapy tailored to the patient's needs allowing for patient-centred optimisation of tinnitus burden and secondary comorbidities. This may include relaxation, CBT and advice surrounding sound as well as white noise masking therapy.